[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Venizelos ID, Tatsiou ZA, Mandala E: Primary cutaneous T-cell-rich B-cell lymphoma: a case report and literature review. Acta Dermatovenerol Alp Pannonica Adriat; 2008 Dec;17(4):177-81
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous T-cell-rich B-cell lymphoma: a case report and literature review.
  • T-cell-rich B-cell lymphoma (TCRBCL) is a recently recognized B-cell lymphoma variant, characterized by a minor population of neoplastic B-cells existing in a background of predominant reactive T-lymphocytes.
  • It is a rare entity, accounting for approximately 1 to 2% of all non-Hodgkin's lymphomas.
  • Primary cutaneous TCRBCL is an extremely rare lymphoma and only 16 cases have been documented thus far in the medical literature.
  • A complete surgical excision of the skin lesion and systemic chemotherapy seems to have been effective because the patient is disease-free 2 years after the initial diagnosis was made.
  • Because of its rarity, it is especially important to make the correct diagnosis using the appropriate immunohistochemical stains and apply the proper therapy.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Lymphoma, B-Cell / pathology. Scalp / pathology. Skin Neoplasms / pathology. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19104743.001).
  • [ISSN] 1318-4458
  • [Journal-full-title] Acta dermatovenerologica Alpina, Pannonica, et Adriatica
  • [ISO-abbreviation] Acta Dermatovenerol Alp Pannonica Adriat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Slovenia
  • [Number-of-references] 25
  •  go-up   go-down


2. Yaich S, Zagdane S, Charfeddine K, Hssairi D, Hachicha J: Simultaneous Hodgkin's disease and Kaposi sarcoma in a renal transplant recipient. Saudi J Kidney Dis Transpl; 2010 Mar;21(2):306-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous Hodgkin's disease and Kaposi sarcoma in a renal transplant recipient.
  • She received induction therapy with antithymoglobulin (ATG) as standard protocol and maintained on immunosuppressive treatment of cyclosporine A, mycophenolate mofetil (MMF), and prednisone.
  • Cutaneous Kaposi's sarcoma and a Hodgkin disease were diagnosed.
  • She also received a poly-chemotherapy associated with 4 courses of rituximab.
  • [MeSH-major] Hodgkin Disease / etiology. Immunosuppressive Agents / adverse effects. Kidney Transplantation / adverse effects. Neoplasms, Multiple Primary. Sarcoma, Kaposi / etiology. Skin Neoplasms / etiology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Therapy, Combination. Female. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20228518.001).
  • [ISSN] 1319-2442
  • [Journal-full-title] Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
  • [ISO-abbreviation] Saudi J Kidney Dis Transpl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


3. Mukesh M, Shuttleworth D, Murray P: Primary cutaneous Hodgkin's lymphoma. Clin Exp Dermatol; 2009 Dec;34(8):e673-5
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous Hodgkin's lymphoma.
  • Cutaneous involvement in Hodgkin's lymphoma is an uncommon but well-recognized condition that usually occurs with advanced-stage disease.
  • Primary cutaneous Hodgkin's disease (PCHD) is exceedingly rare, with only a few reported cases.
  • We report a case of a man treated with combination systemic chemotherapy for PCHD, and review the available literature.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Bleomycin / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817768.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  • [Number-of-references] 10
  •  go-up   go-down


Advertisement
4. Khalifeh I, Hughey LC, Huang CC, Reddy VV, Sellheyer K: Solitary plaque on the scalp as a primary manifestation of Hodgkin lymphoma: a case report and review of the literature. J Cutan Pathol; 2009 Oct;36 Suppl 1:80-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary plaque on the scalp as a primary manifestation of Hodgkin lymphoma: a case report and review of the literature.
  • Cutaneous Hodgkin lymphoma is infrequent and typically occurs after extensive involvement of the lymph nodes.
  • The condition decreased significantly in incidence in the past two decades, likely owing to the new treatment protocols composed of chemotherapy, radiotherapy and stem cell transplantation.
  • Nevertheless, recognition of this uncommon but significant disease manifestation is important from a prognostic and therapeutic perspective.
  • We are sharing a recent case of Hodgkin lymphoma where the primary presentation appeared as a solitary plaque on the left side of the occipital scalp, clinically suspected to represent a ruptured follicular cyst.
  • Histological assessment revealed Hodgkin lymphoma affecting the skin.
  • However, two enlarged lymph nodes were identified in the mediastinum and were positron emission tomography avid.
  • The patient underwent systemic treatment without further histopathological examination of these two lymph nodes.
  • Not being clear if these enlarged two lymph nodes were related to his cutaneous disease or not, we cannot be sure if the patient was afflicted either by primary cutaneous Hodgkin lymphoma or by secondary cutaneous involvement because of hematogenous spread.
  • In either case, primary or secondary cutaneous Hodgkin disease is an extreme rarity.
  • [MeSH-major] Hodgkin Disease / pathology. Scalp / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Immunohistochemistry. Male

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19775396.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 32
  •  go-up   go-down


5. Terao H, Kiryu H, Ohshima K, Kikuchi M, Furue M: Cutaneous CD30 (Ki-1)-positive anaplastic large cell lymphoma preceded by Hodgkin's disease. J Dermatol; 2000 Mar;27(3):170-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous CD30 (Ki-1)-positive anaplastic large cell lymphoma preceded by Hodgkin's disease.
  • A 38-year-old female was diagnosed as Hodgkin's disease of the axillar lymph nodes, nodular sclerosis type, as evidenced by the presence of Reed-Sternberg cells positive for CD30 and CD15 and negative for CD3, CD20, and CD45.
  • She achieved complete remission after combination chemotherapy.
  • These findings were mostly compatible with CD30 (Ki-1)-positive anaplastic large cell lymphoma (Ki-1 lymphoma).
  • Our case is considered to be cutaneous Ki-1 lymphoma preceded by Hodgkin's disease.
  • [MeSH-major] Antigens, CD30 / analysis. Antigens, Neoplasm / analysis. Hodgkin Disease / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Axilla. Biopsy. Female. Humans. Lymph Nodes / pathology


6. Scarisbrick JJ, Child FJ, Clift A, Sabroe R, Whittaker SJ, Spittle M, Russell-Jones R: A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma. Br J Dermatol; 2001 May;144(5):1010-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma.
  • BACKGROUND: The combination of fludarabine and cyclophosphamide shows synergistic toxicity in vitro and has been used to treat nodal non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukaemia.
  • OBJECTIVES: To test the efficacy of this combination in 12 patients with cutaneous T-cell lymphoma (CTCL).
  • Five with SS had a response (one had a complete clinical response and four a partial response) and one patient with MF had stable disease.
  • Six patients had treatment withdrawn, five due to bone marrow suppression and one due to progressive disease.
  • No difference in pretrial parameters were found in those who had treatment withdrawn and those who tolerated at least three courses.
  • As with other multiagent chemotherapy regimens, bone marrow toxicity is a common and severe side-effect.
  • These data suggest that this regimen should be considered palliative and should be reserved for patients with refractory disease without bone marrow suppression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Skin Neoplasms / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Aged. Cyclophosphamide / administration & dosage. Female. Follow-Up Studies. Humans. Middle Aged. Mycosis Fungoides / drug therapy. Pilot Projects. Sezary Syndrome / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11359390.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


7. Visco C, Medeiros LJ, Jones D, Smith T, Rodriguez MA, McLaughlin P, Romaguera J, Cabanillas F, Sarris AH: Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement. Ann Oncol; 2002 Aug;13(8):1290-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement.
  • BACKGROUND: The aim of this study was to explore the association between extent of cutaneous involvement, presenting features and progression-free survival (PFS) in patients with primary cutaneous non-Hodgkin's lymphoma (PCNHL) of aggressive histology.
  • METHODS: Previously untreated patients with localized or extensive PCNHL of aggressive histology, treated with combination chemotherapy, but excluding lymphoblastic lymphoma and mycosis fungoides and its variants, were reviewed retrospectively.
  • Median age was 52 years (range 25-81 years), and disease was localized and extensive in 37 and 16 patients, respectively.
  • Twenty-four patients had diffuse large B-cell lymphoma, nine had grade 3 follicular lymphoma, 13 had peripheral T-cell lymphoma (PTCL; not otherwise specified) and seven had anaplastic large cell lymphoma (WHO classification).
  • CONCLUSIONS: PTCL and elevated serum LDH level, but not extent of cutaneous involvement are associated with inferior PFS in aggressive PCNHL treated with combination chemotherapy.

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12181254.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-16672
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


8. Colovic N, Jurisic V, Terzic T, Atkinson HD, Colovic M: Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin's lymphoma. Arch Dermatol Res; 2009 Oct;301(9):689-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin's lymphoma.
  • The case of a 44-year-old man with a primary cutaneous large B-cell non-Hodgkin's lymphoma of the scalp is reported.
  • His mother died of gastric lymphoma and his sib brother is in a 20-year remission of T-cell lymphoma.
  • The histopathology and immunohistochemistry performed in April 2006 indicated a bcl-6+, MUM- and bcl-2-, primary cutaneous follicle center B-cell non-Hodgkin's lymphoma, with an aggressive transformation to a diffuse large B-cell lymphoma.
  • Bone marrow biopsy and CT chest, abdomen, and pelvis were negative for systemic lymphoma.
  • The protracted indolent phase of the disease, the familial history of lymphoma, the histological aggressive features and the patient's excellent response to immunochemotherapy all contribute to a very unusual manifestation of this disease.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antigens, Neoplasm / metabolism. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Immunotherapy. Injections, Intravenous. Male. Prednisone / therapeutic use. Proto-Oncogene Proteins c-bcl-2 / metabolism. Rituximab. Treatment Outcome. Vesicular Transport Proteins / metabolism. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19495780.001).
  • [ISSN] 1432-069X
  • [Journal-full-title] Archives of dermatological research
  • [ISO-abbreviation] Arch. Dermatol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / BCL2L15 protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / TRAPPC1 protein, human; 0 / Vesicular Transport Proteins; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


9. Hallermann C, Kaune KM, Tiemann M, Kunze E, Griesinger F, Mitteldorf C, Bertsch HP, Neumann C: High frequency of primary cutaneous lymphomas associated with lymphoproliferative disorders of different lineage. Ann Hematol; 2007 Jul;86(7):509-15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High frequency of primary cutaneous lymphomas associated with lymphoproliferative disorders of different lineage.
  • In patients suffering from primary cutaneous lymphomas, secondary malignancies of various origin may develop.
  • We screened all our patients with primary cutaneous lymphomas from a 4-year recruitment period for a coexisting secondary lymphoproliferative disorder.
  • The cohort comprised of a total of 82 patients with primary cutaneous lymphomas, 62 with primary cutaneous T-cell lymphoma (CTCL), 18 with primary cutaneous B-cell lymphomas, and two with CD4+/CD56+ hematodermic neoplasm/blastic lymphomas.
  • Seven patients (8.5%) were identified with a coexisting lymphoma of a different lymphoid lineage.
  • Four patients with Sézary syndrome (SS) suffered from systemic B-cell lymphoma.
  • Two of these developed SS after chemotherapy of their B-cell lymphoma.
  • The other three patients with various types of skin lymphomas (SS, Mycosis fungoides [MF], primary cutaneous marginal zone lymphoma) developed Hodgkin's disease (hairy cell leukemia).
  • Our data indicate that patients with primary cutaneous lymphomas have an elevated risk for the development of a secondary lymphoproliferative disorder even without previous chemotherapy.
  • Possible explanations for this association include a genetic predisposition, alterations in early progenitor cells, underlying viral infections, and/or stimulation of a B-cell clone by the malignant helper T cells of the primary CTCL and vice versa.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / complications. Lymphoproliferative Disorders / complications. Neoplasms, Second Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Hematol. 2007 Jul;86(7):517. Kaune, Matthias Kjell [corrected to Kaune, Kjell Matthias]
  • [ErratumIn] Ann Hematol. 2007 Jul;86(7):517
  • (PMID = 17340135.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, Audring H, Sterry W: Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation. Br J Dermatol; 2005 Jul;153(1):167-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
  • BACKGROUND: Primary cutaneous B-cell lymphomas (PCBCLs) are characterized by restriction to the skin and a variable but mostly favourable prognosis.
  • Since 1997 the recombinant, chimeric anti-CD20 antibody rituximab has been used in patients suffering from non-Hodgkin's B-cell lymphomas.
  • Different studies have shown that the effectiveness and safety in the treatment of patients with low-grade follicular lymphoma is comparable to or even higher than the standard CHOP chemotherapy.
  • So far it has been unclear whether an extended duration of therapy leads to a benefit for the patients with PCBCL.
  • OBJECTIVES: To evaluate the objective response rate, time to progression, remission quality and histological changes and to compare our data with the literature.
  • PATIENTS/METHODS: Ten patients with PCBCL [eight with follicle centre cell lymphoma (FCCL), one with marginal zone lymphoma (MZL) and one with diffuse large B-cell lymphoma of the leg (DLBCL)] were treated by intravenous application of a chimeric antibody against the CD20 transmembrane antigen (rituximab) with a dosage of eight cycles, 375 mg m(-2) body surface, weekly.
  • RESULTS: The treatment regimen resulted in clinical overall response in 9 of 10 patients, in particular there were seven complete responses (70%) plus two partial responses (20%).
  • In two patients no histology was taken after treatment; one patient developed a new lesion.
  • CONCLUSIONS: Intravenous therapy with eight cycles of the anti-CD20 antibody rituximab is a non-toxic and effective treatment for a subset of patients with PCBCL (relapsed, aggressive entity, old patients, multiple lesions) with a long DR.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / immunology. Disease Progression. Disease-Free Survival. Drug Administration Schedule. Drug Evaluation. Humans. Male. Middle Aged. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous B-Cell Lymphomas.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029344.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 28
  •  go-up   go-down


11. Scarisbrick JJ, Child F, Spittle M, Calonje E, Russell-Jones R: Systemic Hodgkin's lymphoma in a patient with Sézary syndrome. Br J Dermatol; 2000 Apr;142(4):771-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic Hodgkin's lymphoma in a patient with Sézary syndrome.
  • We report a case of a 71-year-old male with Sézary syndrome diagnosed in 1996 who subsequently developed systemic Hodgkin's lymphoma.
  • His only past treatment was bath psoralen plus ultraviolet A.
  • He has since been treated with multiagent chemotherapy (ChlVPP/PABLOE) which induced a remission in his Hodgkin's disease.
  • Eighteen months later he remains in remission from Hodgkin's disease but the Sézary syndrome remains active.
  • He has also developed a squamous cell carcinoma on the upper lip.
  • Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by a malignant proliferation of CD4-positive cells in the skin and peripheral circulation.
  • Immunosuppression is known to be associated with an increased rate of malignancies and this may account for the occurrence of Hodgkin's disease and squamous cell carcinoma in this patient with Sézary syndrome.
  • [MeSH-major] Carcinoma, Squamous Cell. Hodgkin Disease. Lip Neoplasms. Neoplasms, Multiple Primary. Sezary Syndrome. Skin Neoplasms
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Immune Tolerance / immunology. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Sezary syndrome.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10792230.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


12. Fierro MT, Savoia P, Quaglino P, Novelli M, Barberis M, Bernengo MG: Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases. J Am Acad Dermatol; 2003 Aug;49(2):281-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases.
  • BACKGROUND: Rituximab, a chimeric antibody directed against CD20, has a high therapeutic value in refractory/relapsed low-grade or follicular B-cell non-Hodgkin's lymphomas as a monotherapy or in combination with polychemotherapy.
  • OBJECTIVES: We sought to evaluate the clinical activity and toxicity of a schedule foreseeing the use of intravenous rituximab preceded by single-dose cyclophosphamide in the treatment of patients with primary cutaneous B-cell lymphoma who progressed and relapsed after chemotherapy.
  • METHODS: A total of 7 patients were treated; 4 had both cutaneous lesions and nodal or visceral involvement.
  • All the patients had been previously treated with at least 1 standard chemotherapy regimen, and 4 with 2 or more, with a median response duration of 8 months.
  • Immunohistochemistry on frozen sections was performed with monoclonal antibodies directed against CD20, CD55, and CD59 before rituximab treatment.
  • RESULTS: The overall objective response rate was 85.7%, with a complete response in 5 patients; treatment was well tolerated in all cases.
  • After a median follow-up of 13 months, 2 patients showed a cutaneous relapse.
  • The response durations of the remaining patients who were disease-free are now 5, 7, 17, and 18 months.
  • CONCLUSION: Although a longer follow-up period is needed to confirm these data, our results are encouraging, particularly in terms of disease-free survival.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Cyclophosphamide / therapeutic use. Lymphoma, B-Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / metabolism. Drug Administration Schedule. Drug Therapy, Combination. Female. Flow Cytometry. Humans. Male. Middle Aged. Recurrence. Rituximab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12894078.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


13. Kirova YM, Dumont J, Validire P, Vincent-Salomon A, Decaudin D, Clough CB, Servois V, Savignoni A, Fourquet A: Management of localized primary breast B-cell Non-Hodgkin's Lymphoma: Role of CNS prophylaxis. J Clin Oncol; 2004 Jul 15;22(14_suppl):6722

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of localized primary breast B-cell Non-Hodgkin's Lymphoma: Role of CNS prophylaxis.
  • : 6722 Background:to evaluate the results of combined treatment modality with doxorubicin-based chemotherapy (C), locoregional radiotherapy (RT) and CNS prophylaxis in NHL of the breast.
  • METHODS: From 1984 to 1999, 20 female pts with diffuse large B-cell lymphoma of the breast, were treated at the Curie Institute.
  • The C protocols were: time-modified CHOP: D1, 10, 20,35,50,65 (n=14) or MACOP-B variant (n=3), both with IT MTX and araC.
  • Total dose was 40 Gy in 20-22 fractions using megavoltage photons.
  • RT to CNS (18 Gy/10 fr.) was delivered in the same time.
  • The CR rate was 100% at the end of treatment.
  • Relapses included lymph nodes (3); LN+breast (2); cutaneous (1), GI (1).
  • CONCLUSIONS: CNS prophylaxis by IT C and CNS RT could prevent CNS relapses in pts with primary breast LNH.
  • Though all pts had CR following treatment, relapses occurred in 40% of the pts including late relapses.
  • Prospective studies are needed to improve the long-term results and define the modality of CNS prophylaxis in this rare but aggressive disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014671.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Querfeld C, Nagelli LV, Rosen ST, Kuzel TM, Guitart J: Bexarotene in the treatment of cutaneous T-cell lymphoma. Expert Opin Pharmacother; 2006 May;7(7):907-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bexarotene in the treatment of cutaneous T-cell lymphoma.
  • Primary cutaneous T-cell lymphomas encompass a spectrum of non-Hodgkin's lymphomas that are characterised by clonal proliferation of skin-homing malignant T lymphocytes.
  • Mycosis fungoides and the leukaemic variant Sézary syndrome, collectively referred to as cutaneous T-cell lymphomas, are the most common entities.
  • No curative therapy exists and patients ultimately develop advanced or relapsed disease that is refractory to standard treatment options.
  • Therefore, there is a great need for the development of novel emerging therapies.
  • Bexarotene is the first synthetic nuclear retinoid X receptor-selective retinoid approved by the FDA for the treatment of refractory cutaneous T-cell lymphoma in all stages, as both an oral capsule and a topical gel formulation.
  • Bexarotene was found to induce apoptosis in a variety of preclinical in vitro and in vivo models including cutaneous T-cell lymphoma cells, and has shown efficacy in two multi-centre, open-label Phase II - III clinical trials for early and advanced stages of cutaneous T-cell lymphoma in patients who have failed or were refractory to standard therapies.
  • New insights into the immunomodulatory function of bexarotene have indicated opportunities for combined treatment with IFN-alpha, denileukin diftitox or phototherapy.
  • This article reviews the biological properties, pharmacokinetics, clinical efficacy, safety and role of bexarotene in the treatment of cutaneous T-cell lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16634713.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 72
  •  go-up   go-down


15. Wollina U, Graefe T, Karte K: Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol; 2000 Jan;42(1 Pt 1):40-6
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin.
  • BACKGROUND: Pegylated liposomes are stable, long-circulating carriers useful for delivering doxorubicin to tumor sites with a lower toxicity than the free drug.
  • Free doxorubicin is used in several treatment protocols for non-Hodgkin's lymphoma.
  • Although pegylated liposomal doxorubicin is currently used in the treatment of Kaposi's sarcoma, no data are available for tumors, such as primary cutaneous T-cell lymphomas (CTCLs).
  • Six patients (1 woman and 5 men) aged 59 to 78 years with relapsing or recalcitrant CTCL of the mycosis fungoides type, stage (Ib/IIb), were treated with pegylated liposomal doxorubicin to induce a clinical response.
  • The drug was administered at a dosage of 20 mg m(-2) once a month.
  • The final outcome was a complete response in 4, a partial response in 1, and progressive disease in 1 patient (overall response rate, 83%).
  • There was no need of additional therapy because of side effects.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Doxorubicin / administration & dosage. Mycosis Fungoides / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Drug Carriers. Female. Humans. Infusions, Intravenous. Liposomes. Male. Middle Aged. Pilot Projects. Polyethylene Glycols. Prospective Studies. Recurrence

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Acad Dermatol. 2001 Jan;44(1):149-50 [11148501.001]
  • (PMID = 10607318.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Carriers; 0 / Liposomes; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin
  •  go-up   go-down


16. Breccia M, Petti MC, D'Elia GM, D'Andrea M, Carmosino I, Alimena G: Cutaneous pleomorphic T-cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine-containing regimen. Eur J Haematol; 2002 Jan;68(1):1-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous pleomorphic T-cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine-containing regimen.
  • The coexistence of a primary myelodysplastic syndrome (MDS) and a T-cell cutaneous non-Hodgkin's lymphoma is an extremely rare event, which has so far only been reported in a single instance in the literature.
  • We describe herein an additional case in which the lymphoid disease was combined with an MDS at the time of its evolution into acute myeloid leukemia (AML).
  • We discuss possible pathogenetic mechanisms and suggest the use of nonalkylating drugs, such as fludarabine, for the treatment of this rare association of malignancies usually characterized by a very poor response to therapy.
  • [MeSH-major] Anemia, Refractory, with Excess of Blasts / complications. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Lymphoma, T-Cell, Cutaneous / complications. Neoplasms, Second Primary / drug therapy. Skin Neoplasms / complications
  • [MeSH-minor] Aged. Antineoplastic Agents, Alkylating / contraindications. Bone Marrow / pathology. Cytarabine / administration & dosage. Disease Progression. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Immunophenotyping. Male. Methotrexate / administration & dosage. Remission Induction. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives


17. Prunier F, Revel F, Hemery Y, Glaser E, Beaufils P: [Malignant non-Hodgkin's lymphoma presenting with arrhythmia and conduction defects. Report of 2 cases]. Arch Mal Coeur Vaiss; 2000 Nov;93(11):1333-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant non-Hodgkin's lymphoma presenting with arrhythmia and conduction defects. Report of 2 cases].
  • Primary cardiac lymphoma is very rare.
  • The authors report two cases, the first of a 35 year old man in whom primary cardiac lymphoma presented with ventricular tachycardia complicated secondarily by complete atrioventricular block (AVB) with pseudo-inferior wall infarction.
  • The second case was a 37 year old man with a cutaneous T cell lymphoma in whom complete AVB was the first sign of a secondary cardiac localisation of his disease.
  • The finding of cardiac lymphoma should lead to aggressive chemotherapy as soon as possible.
  • [MeSH-major] Heart Block / etiology. Heart Neoplasms / secondary. Lymphoma, Non-Hodgkin / complications. Tachycardia, Ventricular / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11190461.001).
  • [ISSN] 0003-9683
  • [Journal-full-title] Archives des maladies du coeur et des vaisseaux
  • [ISO-abbreviation] Arch Mal Coeur Vaiss
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


18. Sréter L: [Therapy in Hodgkin disease and non-Hodgkin lymphomas]. Orv Hetil; 2009 Apr 5;150(14):651-5
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy in Hodgkin disease and non-Hodgkin lymphomas].
  • [Transliterated title] A Hodgkin- és a non-Hodgkin-lymphomák kezelése.
  • The therapy of malignant lymphoproliferative diseases has changed many times in recent years.
  • Treatment strategy of Hodgkin's disease is now based on risk adaptation, including not only the results of pretreatment diagnostic and prognostic factors but also the repeated PET/CT (restaging) made in the early treatment period.
  • Possible reduction of irradiation therapy may contribute to lower the risk of secondary tumors, which are common late complications of radiochemotherapy.
  • Autologous stem cell transplantation is the therapy of choice in chemosensitive relapsing patients.
  • The complete remission rate today in Hodgkin's disease is around 85%.
  • In the heterogenic group of Non-Hodgkin Lymphomas, progression of indolent lymphomas (CLL, multiple myeloma, hairy cell leukemia, cutaneous lymphomas, etc.) is slow in case of natural course.
  • Their therapy is mostly palliative and complete remission with the latest treatment modalities is not possible.
  • Aggressive lymphomas are characterized with rapid progression and early death without treatment.Most of them respond to chemotherapy and irradiation.With an adequate therapy, 60-70% of patients reach complete remission (CR) and 40-50% of them remain in remission.
  • Using immune- and radioimmune therapy in indolent and aggressive NHL groups gives possibility to influence G0 tumor cells as well.
  • Their use in combination with classic chemotherapy leads to more complete remissions and better therapy results.
  • The introduction of routine PET/CT made the first and repeated staging of NHL more precise and contributed to more effective treatment.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Neoplasms, Second Primary / prevention & control
  • [MeSH-minor] Disease Progression. Humans. Leukemia, Hairy Cell / diagnosis. Leukemia, Hairy Cell / therapy. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Multiple Myeloma / diagnosis. Multiple Myeloma / therapy. Neoplasm Staging. Positron-Emission Tomography. Remission Induction. Stem Cell Transplantation. Tomography, X-Ray Computed. Transplantation, Autologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19318337.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


19. LeMaistre CF: DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications. Clin Lymphoma; 2000 Nov;1 Suppl 1:S37-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The activity of DAB(389)IL-2 in the treatment of cutaneous T-cell lymphoma has established the feasibility of utilizing such a targeted therapeutic in disseminated disease with acceptable toxicity.
  • Data from the phase I trial suggest that the definition of activity in other cancer types, including other non-Hodgkin's lymphomas (NHL), is warranted.
  • Three NHL patients in this study responded, two of whom had follicular lymphomas, with the third having a primary intermediate-grade B-cell NHL that was refractory to chemotherapy and stem cell transplant.
  • This patient has remained in complete remission over 3 years after treatment with DAB(389)IL-2.
  • The need for a threshold level of receptor expression, the difficulty in obtaining representative tissue, the lack of an assay that accurately reflects high-affinity receptor, and the potential difficulty of observer variability in evaluating the assays should point us toward examining response rates in cancer patients where IL-2R cannot be detected or is unknown.
  • Targeting IL-2R-expressing lymphocytes may be an effective strategy for the prevention of graft rejection and to treat or prevent graft-versus-host disease.
  • The potential utility in other autoimmune disorders is unknown, but diseases such as systemic lupus, scleroderma, and vasculitis also may be effective candidates for such ligand fusion therapy.
  • [MeSH-major] Diphtheria Toxin / therapeutic use. Immunosuppressive Agents / therapeutic use. Immunotoxins / therapeutic use. Interleukin-2 / therapeutic use. Recombinant Fusion Proteins / therapeutic use
  • [MeSH-minor] Arthritis, Rheumatoid / drug therapy. Autoimmune Diseases / drug therapy. Clinical Trials as Topic. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, T-Cell, Cutaneous / drug therapy. Psoriasis / drug therapy. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11707862.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphtheria Toxin; 0 / Immunosuppressive Agents; 0 / Immunotoxins; 0 / Interleukin-2; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox
  • [Number-of-references] 19
  •  go-up   go-down


20. Greer JP, Kinney MC, Loughran TP Jr: T cell and NK cell lymphoproliferative disorders. Hematology Am Soc Hematol Educ Program; 2001;:259-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Problems with PTCL include their rarity, representing usually 10-15% of non-Hodgkin's lymphomas in the Western Hemisphere, morphologic heterogeneity, and lack of immunophenotypic markers for clonality.
  • Emphasis will be placed on extranodal T cell and natural killer (NK) cell lymphomas such as hepatosplenic lymphoma, subcutaneous panniculitis-like lymphoma and nasal/nasal type T/NK-cell lymphoma.
  • The use of ALK gene regulation in the classification of anaplastic large cell lymphoma is also reviewed. Dr.
  • The discussion focuses on LGL leukemia as an instructive model of dysregulated apoptosis causing both malignant and autoimmune disease.
  • Current management options and mechanisms of therapeutic response are also described. Dr.
  • He discusses the therapeutic options for anaplastic large cell lymphoma (ALCL), from a conservative approach for primary cutaneous ALCL to combination chemotherapy for the highly chemosensitive ALCL expressing anaplastic lymphoma kinase.
  • He reviews therapy options for the extranodal subtypes of PTCL by drawing from series in adults, pediatrics, dermatology, and the Far East.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11722988.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 241
  •  go-up   go-down


21. Introcaso CE, Kantor J, Porter DL, Junkins-Hopkins JM: Cutaneous Hodgkin's disease. J Am Acad Dermatol; 2008 Feb;58(2):295-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous Hodgkin's disease.
  • Cutaneous Hodgkin's disease is a rare condition that usually occurs late in the course of Hodgkin's lymphoma.
  • This rare condition is thought to have decreased in incidence in recent decades, likely owing to improved treatment of patients with Hodgkin's disease, who are receiving improved chemotherapy and radiation therapy, and the advent of peripheral blood stem cell transplantation.
  • We present the case of a man who developed specific cutaneous Hodgkin's lymphoma 6 months after nonmyeloablative allogenic stem cell transplantation for his recurrent systemic disease.
  • The patient's manifestation of relapse was cutaneous dissemination of the tumor, manifested by erythematous papules and ulcerated nodules.
  • At the time of the cutaneous relapse he had minimal systemic disease.
  • This case illustrates an example of this complication of Hodgkin's disease and stresses the importance of a timely diagnosis to direct appropriate therapy.
  • A review of the literature demonstrates that the patient's lesion morphology and distribution are typical of specific manifestations of cutaneous Hodgkin's disease.
  • [MeSH-major] Hodgkin Disease / complications. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18222326.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


22. Duvic M, Foss FM: Mycosis fungoides: pathophysiology and emerging therapies. Semin Oncol; 2007 Dec;34(6 Suppl 5):S21-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mycosis fungoides: pathophysiology and emerging therapies.
  • Primary cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of non-Hodgkin's lymphomas characterized by skin infiltration of neoplastic T lymphocytes.
  • Current treatment for patients with mycosis fungoides involves topical and systemic therapies for the cutaneous manifestations.
  • However, no therapy is curative and patients often progress to advanced extracutaneous CTCL with visceral organ complications or relapsed disease that is frequently refractory to most topical and aggressive systemic regimens.
  • The emergence of novel targeted therapies such as biologic agents, histone deacetylase inhibitors, and purine nucleoside phosphorylase inhibitors offers promise for more effective and safer treatment strategies for refractory CTCLs.
  • [MeSH-major] Histone Deacetylases / drug effects. Mycosis Fungoides. Purine-Nucleoside Phosphorylase / drug effects. Skin Neoplasms
  • [MeSH-minor] Clinical Trials as Topic. Humans. Immunologic Factors / therapeutic use. Purine Nucleosides / therapeutic use. Pyrimidinones / therapeutic use. Sezary Syndrome / drug therapy. Sezary Syndrome / physiopathology

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18086343.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / Purine Nucleosides; 0 / Pyrimidinones; 426X066ELK / forodesine; EC 2.4.2.1 / Purine-Nucleoside Phosphorylase; EC 3.5.1.98 / Histone Deacetylases
  • [Number-of-references] 56
  •  go-up   go-down






Advertisement